Gene Mack, Gain Therapeutics CEO, provides a look into the future of the company and the use of physics-based artificial ...

The leaders who make space for strategic pauses aren’t the ones who fall behind—they’re the ones who set the pace for ...

Fintel reports that on February 13, 2025, Leerink Partners downgraded their outlook for 10x Genomics (NasdaqGS:TXG) from ...

Yale researchers have created "Ochre," a genomically recoded organism that enables the production of synthetic proteins with ...

Unfortunately, there isn't an enzyme for many reactions we would sorely like to catalyze—things like digesting plastics or ...

Recursion Pharmaceuticals struggles with validation of REC-994 and competition in oncology. Read why RXRX stock is a hold ...

You’re reading the web edition of STAT’s Health Tech newsletter, our guide to how technology is transforming the life ...

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Nvidia Corporation's AI chip dominance remains solid despite DeepSeek's claims. Click for why NVDA's ecosystem, innovation, ...